These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32939056)

  • 1. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1.
    Kalaw E; Lim M; Kutasovic JR; Sokolova A; Taege L; Johnstone K; Bennett J; Saunus JM; Niland C; Ferguson K; Gresshoff I; Bettington M; Pathmanathan N; Tse GM; Papadimos D; Pathmanathan R; Harris G; Yamaguchi R; Tan PH; Fox S; O'Toole SA; Simpson PT; Lakhani SR; McCart Reed AE
    Br J Cancer; 2020 Nov; 123(11):1665-1672. PubMed ID: 32939056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
    Burugu S; Gao D; Leung S; Chia SK; Nielsen TO
    Ann Oncol; 2017 Dec; 28(12):2977-2984. PubMed ID: 29045526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of immune density, PD-L1, and CXCR4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.
    Bagbudar S; Karanlık H; Cabioglu N; Bayram A; Tükenmez M; Aydıner A; Yavuz E; Onder S
    Med Oncol; 2023 Dec; 41(1):18. PubMed ID: 38102446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
    Bonanno L; Pavan A; Dieci MV; Di Liso E; Schiavon M; Comacchio G; Attili I; Pasello G; Calabrese F; Rea F; Favaretto A; Rugge M; Guarneri V; Fassan M; Conte PF
    Eur J Cancer; 2018 Sep; 101():191-200. PubMed ID: 30077124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune parameters associated with survival in metaplastic breast cancer.
    Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
    Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
    Wang X; Liu Y
    Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.
    Lien HC; Lee YH; Chen IC; Lin CH; Chen TW; Lu YT; Lu YS
    Virchows Arch; 2021 Apr; 478(4):669-678. PubMed ID: 33089401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
    Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer.
    Hirakata T; Fujii T; Kurozumi S; Katayama A; Honda C; Yanai K; Tokuda S; Nakazawa Y; Obayashi S; Yajima R; Kaira K; Oyama T; Shirabe K
    Breast Cancer Res Treat; 2020 Jun; 181(2):331-338. PubMed ID: 32253685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune characterization of breast cancer metastases: prognostic implications.
    Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
    Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor.
    Won KY; Kim GY; Kim HK; Song MJ; Choi SI; Bae GE; Lim SJ
    Pathol Res Pract; 2019 Nov; 215(11):152639. PubMed ID: 31582185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of immune microenvironment in gastrointestinal stromal tumours.
    Blakely AM; Matoso A; Patil PA; Taliano R; Machan JT; Miner TJ; Lombardo KA; Resnick MB; Wang LJ
    Histopathology; 2018 Feb; 72(3):405-413. PubMed ID: 28871595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
    Ren M; Dai B; Kong YY; Lv JJ; Cai X
    Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.
    Kim A; Lee SJ; Kim YK; Park WY; Park DY; Kim JY; Lee CH; Gong G; Huh GY; Choi KU
    Sci Rep; 2017 Sep; 7(1):11671. PubMed ID: 28916815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.